MiR-155和miR-21在乳腺癌分子亚型诊断中的价值

doi:10.3969/j.issn.2095-378X.2017.04.001

外科研究与新技术 ›› 2017, Vol. 6 ›› Issue (4): 229-234.doi: 10.3969/j.issn.2095-378X.2017.04.001

• 论著 • 下一篇

MiR-155和miR-21在乳腺癌分子亚型诊断中的价值

徐明¹, 谢轶群², 朱佳慧¹, 黄斌¹

1.黄浦区中心医院病理科,上海 200002;
2.黄浦区中心医院乳腺外科,上海 200002

收稿日期:2017-10-23 发布日期:2017-12-28
通讯作者: 黄斌,电子邮箱:chmbcitizen@net.com
作者简介:徐明(1969—),男,主任医师,从事乳腺疾病病理学
基金资助:
黄浦区优秀学科带头人项目,黄浦区卫计委科研项目(HKW201412)

Value of miR-155 and miR-21 in diagnosis of molecular subtypes of breast cancer

XU Ming¹, XIE Yiqun², ZHU Jiahui¹, HUANG Bin¹

1.Department of Pathology,Huangpu District Central Hospital,Shanghai 200002,China;
2.Department of Breast Surgery,Huangpu District Central Hospital,Shanghai 200002,China

Received:2017-10-23 Published:2017-12-28

摘要/Abstract

摘要： 目的探讨miR-21和miR-155在浸润性乳腺癌分子亚型的表达及临床意义。方法收集91例浸润性乳腺癌的临床病理资料,各分子亚型采用RT-PCR方法检测miR-21和miR-155表达量。结果 miR-21在中Luminal A-like型、Luminal B-like型、HER2型和TNBC(triple-negative breast cancer)型的相对表达量分别为0.000±2.238、1.008±1.297、1.627±1.744和0.983±1.630,miR-155的相对表达量分别为 -2.313±1.077、-1.022±1.151、-0.051±0.903和-0.728±1.585,Luminal B-like型、HER2型和TNBC型的miR-155相对表达量与Luminal A-like型相比较差异有统计学意义(P<0.001)。结论检测浸润性乳腺癌中miR-155表达量有可能成为指导Luminal型乳腺癌患者是否需要行化疗的一种新的手段。

关键词: 乳腺癌, 分子亚型, miR-21, miR-155

Abstract: Objective To investigate the expression and clinical significance of miR-21 and miR-155 in the molecular subtypes of invasive breast cancer.Methods The clinicopathologic data of 91 cases of invasive breast cancer were retrieved.The expression levels of miR-21 and miR-155 were detected by qRT-PCR.Results The relative expression levels of miR-21 in luminal A-like,luminal B-like,HER2,and TNBC (triple-negative breast cancer) subtypes of breast cancer were 0.000±2.238,1.008±1.297,1.670±1.774 and 0.983±1.630,respectively,and the relative expression levels of miR-155 were -2.313±1.077,-1.022±1.511,-0.051±0.903 and -0.728±1.585,respectively.There were significant differences in the relative expression levels of miR-155 of luminal B-like,HER2,and TNBC subtypes versus that in luminal A-like subtype (P<0.001).Conclusion Detecting the expression levels of miR-155 in invasive breast cancer may be a new approach for guiding breast cancer patients of luminal type to undertake chemotherapy or not.

Key words: Breast cancer, Molecular subtype, miR-21, miR-155

中图分类号:

R655.8

徐明, 谢轶群, 朱佳慧, 黄斌. MiR-155和miR-21在乳腺癌分子亚型诊断中的价值[J]. 外科研究与新技术, 2017, 6(4): 229-234.

XU Ming, XIE Yiqun, ZHU Jiahui, HUANG Bin. Value of miR-155 and miR-21 in diagnosis of molecular subtypes of breast cancer[J]. Surgical Research and New Technique, 2017, 6(4): 229-234.

参考文献

[1] Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
[2] Coates AS,Winer EP,Goldhirsch A,et al.Tailoring therapies-improving the management of early breast cancer:St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J].Ann Oncol,2015,26(8):1533-1546.
[3] Yoruker EE,Aydogˇan F,Gezer U,et al.Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer[J].Mol Clin Oncol,2015,3(4):954-958.
[4] Gwak JM,Kim HJ,Kim EJ,et al.MicroRNA-9 is associated with epithelial-mesenchymal transition,breast cancer stem cell phenotype,and tumor progression in breast cancer[J].Breast Cancer Res Treat,2014,147(1):39-49.
[5] Lakhani SR,Ellis IO,Schnitt SJ,et al.WHO classification of tumours of the breast[M].4th ed.Lyon:International Agency for Research on Cancer,2012:13-31.
[6] Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.
[7] Lee JA,Lee HY,Lee ES,et al.Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast[J].J Breast Cancer,2011,14(4):269-275.
[8] Chen J,Wang BC,Tang JH.Clinical significance of microRNA-155 expression in human breast cancer[J].J Surg Oncol,2012,106(3):260-266.
[9] 傅少梅,张宏伟,刘默芳,等.MiR-155和miR-21在乳腺癌组织中的表达[J].中华实验外科杂志,2011,28 (8):1240.
[10] Liu J,Mao Q,Liu Y,et al.Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients[J].Chin J Cancer Res,2013,25(1):46-54.
[11] Nina P,Radoslav D,Vladan B,et al.MicroRNA in breast cancer:the association with BRCA1/2[J].Cancer Biomark,2017,19(2):119-128.
[12] Chang S,Wang RH, Akagi K,et al.Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155[J].Nat Med,2011,17(10):1275-1282.
[13] Kong W,He L,Richards EJ,et al.Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer[J].Oncogene,2014,33(6):679-689.

MiR-155和miR-21在乳腺癌分子亚型诊断中的价值

Value of miR-155 and miR-21 in diagnosis of molecular subtypes of breast cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价

[1]	金海龙, 武彪, 张毅. 乳腺癌术后患者不同局部区域复发对预后的影响[J]. 外科研究与新技术, 2020, 9(3): 149-153.
[2]	吴松龄, 张美泽, 刘佳慧, 詹巧惠. 98例早期乳腺癌非前哨淋巴结转移的影响因素分析[J]. 外科研究与新技术, 2020, 9(1): 6-9.
[3]	王永亮, 柴辉, 赵宏卿, 王怀锦, 褚瑞军, 郭思亮, 翟耀君. 他莫昔芬与阿那曲唑乳腺癌内分泌治疗对于骨代谢水平的影响[J]. 外科研究与新技术, 2019, 8(4): 262-264.
[4]	陈蔓青, 吴春山, 佘丹育, 方志潮, 曾灿艺, 许丽珊. 腋窝超声联合亚甲蓝示踪剂在乳腺癌前哨淋巴结活检术中的应用研究[J]. 外科研究与新技术, 2019, 8(3): 163-166.
[5]	贺雪, 殷佩浩. 结直肠癌患者血清miR-21检测的临床价值[J]. 外科研究与新技术, 2019, 8(1): 1-3.
[6]	陈文晓, 袁超杰, 吴卫文, 罗海岸. 溶脂辅助腋窝淋巴结清扫术临床应用分析[J]. 外科研究与新技术, 2019, 8(1): 40-43.
[7]	李燕玲, 刘佩蓉, 庄菊花, 陆伟华, 彭生. 耳穴揿针埋针对乳腺癌手术患者围手术期焦虑的护理干预[J]. 外科研究与新技术, 2018, 7(2): 143-145.
[8]	张辉, 林孟波, 王金泗, 陈晓耕, 范跃祖, 郑敏辉. 早期乳腺癌行保留乳头乳晕全乳切除术并一期乳房重建的治疗效果[J]. 外科研究与新技术, 2018, 7(1): 4-8.
[9]	张辉, 林孟波, 王金泗, 陈晓耕, 范跃祖. 新辅助化疗对乳腺癌腋窝前哨淋巴结状况的影响[J]. 外科研究与新技术, 2017, 6(4): 235-238.
[10]	莫永泮, 杨毅. 乳腺外科整形术在乳腺癌保乳术中的应用价值[J]. 外科研究与新技术, 2017, 6(3): 155-157.
[11]	张涛施宝民王洪崔乃鹏林锐季堃. 乳腺癌前哨淋巴结阳性时非前哨淋巴结转移的相关因素分析[J]. 外科研究与新技术, 2017, 6(1): 1-4.
[12]	张涛施宝民王洪陈鹊汀季堃余松林. 乳腺癌T7 噬菌体展示cDNA文库的构建[J]. 外科研究与新技术, 2015, 4(1): 9-11.
[13]	陈权, 谭鸣. 一起“乳腺癌”病理报告失误导致的医疗事故分析[J]. 外科研究与新技术, 2012, 1(2): 169-170.